Home Tools
Log in
Cart

CDK

Cyclin-dependent kinases (CDKs) are the families of protein kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells.They are present in all known eukaryotes, and their regulatory function in the cell cycle has been evolutionarily conserved.
Signaling Pathways | Target | TargetMol
Cat. No. Product name CAS No. Purity Chemical Structure
T79604 SHR5428 98%
SHR5428
SHR5428 is an orally active, selective, noncovalent inhibitor of CDK7, displaying potent enzymatic inhibition (IC50 = 2.3 nM) and effectively suppressing cellula...
T79606 CAF-382 98%
CAF-382
CAF-382 (compound B1), an analog of SNS-032, functions as a CDKL5 and pan-CDK inhibitor, exhibiting modest inhibitory activity against GSK3α/β with an affinity g...
T79631 CDK9-IN-26 98%
CDK9-IN-26
CDK9-IN-26, also known as compound 1, is a potent inhibitor of Cyclin-Dependent Kinase 9 (CDK9) with an IC50 value of 0.18 μM.[1]
T79640 ZNL-05-044 98%
ZNL-05-044
ZNL-05-044, a CDK11 inhibitor, exhibits IC50 values of 0.23 μM for CDK11A and 0.27 μM for CDK11B, as determined by NanoBRET assay. It induces G2/M cell cycle arr...
T79648 CDK2-IN-19 98%
CDK2-IN-19
CDK2-IN-19 (Compound 32) is a selective, orally active inhibitor of CDK2 (K i: 0.18 nM) that exhibits anticancer activity in mice with OVCAR3 tumors [1].
T79704 CDK9-IN-28 98%
CDK9-IN-28
PROTAC CDK9/CycT1 Degrader-1 (compounds 10), a potent CDK9 inhibitor, serves as a target protein ligand for PROTAC synthesis. Exhibiting substantial anti-prolife...
T79862 Tacaciclib 2768774-66-7 98%
Tacaciclib
Tacaciclib is a cyclin-dependent kinase (CDK) inhibitor with observed antineoplastic activity [1].
T79863 Tibremciclib 2397678-18-9 98%
Tibremciclib
Tibremciclib is a cyclin-dependent kinase 4 (CDK4) inhibitor that exhibits antineoplastic properties [1].
T79881 CDK7-IN-25 2009209-60-1 98%
CDK7-IN-25
CDK7-IN-25 (CY-16-1) is a potent CDK7 inhibitor with an IC50 value of less than 1nM, utilized in cancer research [1].
T79904 PROTAC CDK9/CycT1 Degrader-2 98%
PROTAC CDK9/CycT1 Degrader-2
PROTAC CDK9/CycT1 Degrader-2 inhibits CDK9 with an IC50 of 45 nM [1].
T82757 CDK9-IN-29 2737262-24-5 98%
CDK9-IN-29
CDK9-IN-29 (compound Z11) is a potent inhibitor of CDK9, exhibiting high kinase selectivity and an IC50 value of 3.20 nM. It effectively hinders cell proliferati...
T82758 CDK9-Cyclin T1 PPI-IN-1 98%
CDK9-Cyclin T1 PPI-IN-1
CDK9-Cyclin T1 PPI-IN-1 (Compound B19) is a selective inhibitor of the CDK9-Cyclin T1 protein-protein interaction (PPI), suppressing cell proliferation in TNBC M...
T82759 CDK2-IN-20 98%
CDK2-IN-20
CDK2-IN-20 (compound 3b), a CDK2 inhibitor, exhibits cytotoxic effects on tumor cells with an IC50 ranging from 5.52-17.09 µM. It arrests the MCF-7 cell cycle at...
T10737 CDK4/6-IN-3 2366237-37-6 98%
CDK4/6-IN-3
CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor (Kis: <0.3 nM and 2.2 nM) used for the treatment of glioblastoma. It inhibits CDK1 with a Ki of 110 nM.
T16038 Men 10376 135306-85-3 98%
Men 10376
Men 10376 is a selective antagonist of tachykinin NK-2 receptor. It has a Ki of 4.4 μM for rat small intestine NK-2 receptor.
TN4263 Isoangustone A 129280-34-8 98%
Isoangustone A
Isoangustone A has antitumor activity, it can induce G1 cycle arrest in DU145 human prostate and 4T1 murine mammary cancer cells, it inhibits cell proliferation ...
T11309 FMF-04-159-2 2364489-81-4 98%
FMF-04-159-2
FMF-04-159-2 inhibits CDK14 and CDK2 with IC50s of 39.6 nM and 256 nM in NanoBRET assay, respectively. FMF-04-159-2 is a covalent CDK14 inhibitor.
T10739 CDK8/19-IN-1 1818427-07-4 98%
CDK8/19-IN-1
CDK8/19-IN-1 is a selective and oral bioavailable CDK8/19 dual inhibitor (IC50s: 0.46 nM, 0.99 nM, and 270 nM for CDK8, CDK19, and CDK9).
T15730 Ribociclib hydrochloride 1211443-80-9 98%
Ribociclib hydrochloride
Ribociclib hydrochloride is a highly specific CDK4/6 inhibitor (IC50: 10 nM and 39 nM, respectively). It is over 1,000-fold less potent against the cyclin B/CDK1...
T13425 (1S,3R,5R)-PIM447 dihydrochloride T13425 98%
(1S,3R,5R)-PIM447 dihydrochloride
(1S,3R,5R)-PIM447 (dihydrochloride) an inhibitor of PIM(IC50 of 0.095 μM for Pim1, 0.522 μM for Pim2 and 0.369 μM for Pim3).
SHR5428
T79604
SHR5428 is an orally active, selective, noncovalent inhibitor of CDK7, displaying potent enzymatic inhibition (IC50 = 2.3 nM) and effectively suppressing cellula...
CAF-382
T79606
CAF-382 (compound B1), an analog of SNS-032, functions as a CDKL5 and pan-CDK inhibitor, exhibiting modest inhibitory activity against GSK3α/β with an affinity g...
CDK9-IN-26
T79631
CDK9-IN-26, also known as compound 1, is a potent inhibitor of Cyclin-Dependent Kinase 9 (CDK9) with an IC50 value of 0.18 μM.[1]
ZNL-05-044
T79640
ZNL-05-044, a CDK11 inhibitor, exhibits IC50 values of 0.23 μM for CDK11A and 0.27 μM for CDK11B, as determined by NanoBRET assay. It induces G2/M cell cycle arr...
CDK2-IN-19
T79648
CDK2-IN-19 (Compound 32) is a selective, orally active inhibitor of CDK2 (K i: 0.18 nM) that exhibits anticancer activity in mice with OVCAR3 tumors [1].
CDK9-IN-28
T79704
PROTAC CDK9/CycT1 Degrader-1 (compounds 10), a potent CDK9 inhibitor, serves as a target protein ligand for PROTAC synthesis. Exhibiting substantial anti-prolife...
Tacaciclib
T79862
Tacaciclib is a cyclin-dependent kinase (CDK) inhibitor with observed antineoplastic activity [1].
Tibremciclib
T79863
Tibremciclib is a cyclin-dependent kinase 4 (CDK4) inhibitor that exhibits antineoplastic properties [1].
CDK7-IN-25
T79881
CDK7-IN-25 (CY-16-1) is a potent CDK7 inhibitor with an IC50 value of less than 1nM, utilized in cancer research [1].
PROTAC CDK9/CycT1 Degrader-2
T79904
PROTAC CDK9/CycT1 Degrader-2 inhibits CDK9 with an IC50 of 45 nM [1].
CDK9-IN-29
T82757
CDK9-IN-29 (compound Z11) is a potent inhibitor of CDK9, exhibiting high kinase selectivity and an IC50 value of 3.20 nM. It effectively hinders cell proliferati...
CDK9-Cyclin T1 PPI-IN-1
T82758
CDK9-Cyclin T1 PPI-IN-1 (Compound B19) is a selective inhibitor of the CDK9-Cyclin T1 protein-protein interaction (PPI), suppressing cell proliferation in TNBC M...
CDK2-IN-20
T82759
CDK2-IN-20 (compound 3b), a CDK2 inhibitor, exhibits cytotoxic effects on tumor cells with an IC50 ranging from 5.52-17.09 µM. It arrests the MCF-7 cell cycle at...
CDK4/6-IN-3
T10737
CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor (Kis: <0.3 nM and 2.2 nM) used for the treatment of glioblastoma. It inhibits CDK1 with a Ki of 110 nM.
Men 10376
T16038
Men 10376 is a selective antagonist of tachykinin NK-2 receptor. It has a Ki of 4.4 μM for rat small intestine NK-2 receptor.
Isoangustone A
TN4263
Isoangustone A has antitumor activity, it can induce G1 cycle arrest in DU145 human prostate and 4T1 murine mammary cancer cells, it inhibits cell proliferation ...
FMF-04-159-2
T11309
FMF-04-159-2 inhibits CDK14 and CDK2 with IC50s of 39.6 nM and 256 nM in NanoBRET assay, respectively. FMF-04-159-2 is a covalent CDK14 inhibitor.
CDK8/19-IN-1
T10739
CDK8/19-IN-1 is a selective and oral bioavailable CDK8/19 dual inhibitor (IC50s: 0.46 nM, 0.99 nM, and 270 nM for CDK8, CDK19, and CDK9).
Ribociclib hydrochloride
T15730
Ribociclib hydrochloride is a highly specific CDK4/6 inhibitor (IC50: 10 nM and 39 nM, respectively). It is over 1,000-fold less potent against the cyclin B/CDK1...
(1S,3R,5R)-PIM447 dihydrochloride
T13425
(1S,3R,5R)-PIM447 (dihydrochloride) an inhibitor of PIM(IC50 of 0.095 μM for Pim1, 0.522 μM for Pim2 and 0.369 μM for Pim3).
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
TargetMol